In a report released on March 17, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), with a ...
Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact ...
Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Idorsia Ltd (SIX: IDIA) today announced the publication of“A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research.
Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...
In a report released on February 26, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), ...
Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback